All Type of News
Xarelto’s firm top position and Eliquis’s first 2nd in ranking
The launch of a next-generation novel oral anticoagulant(NOAC) ‘Eliquis(generic name: apixaban)’ attracted attention of the industry as becoming the top 2 prescription product for the first time in the quarter. ‘Xarel...
Green Cross supplies largest amount of first-developed tetravalent flu vaccines
Green Cross, a loyal family in vaccine and the top influenza vaccine company, pushes forward with active moves to continue its reputation.
Green Cross(CEO Eun-cheol Huh) announced it successfully held a launching sym...
Monthly schizophrenia therapy ‘Abilify Maintena’ launched with insurance benefit
A schizophrenia therapy whose patient drug compliance and recurrence control were improved compared to oral drugs, ‘Abilify Maintena’ will be launched this September.
Korea Otsuka Pharmaceuticals(CEO Seung-ho Moon) ...
Pfizer VP Won-sik Lee takes charge in MFDS Pharmaceutical Safety Director
As Pharmaceutical Safety Director at the Ministry of Food and Drug Safety(MFDS), Vice President Won-sik Lee at Pfizer Pharmaceuticals Korea, who graduated Seoul National University College of Medicine, was appointed. ...
Series of Bupropion generic approvals
Is it because of a great advance of an antismoking treatment which recorded KRW 4.2 billion prescriptions last year, Nicopion(generic name: bupropion, Hanmi Pharm)? Multiple pharmaceutical companies attracted attentio...
Pharmicell & Green Cross have largest ratios of R&D employees
1.5 of 10 employees working in pharmaceutical companies were known to engage in the R&D field.
According to the aggregation result of 34 companies who open public the number of researchers and developers in their 20...
Celltrion’s Remsima occupies 40% of original drug market in Europe
The number of European patients who were prescribed the Celltrion’s biosimilar antibody Remsima was observed to exceed approximately 105 thousand people as of the 2nd quarter this year.
According to Celltrion, Remsim...
G-CSF injections extended in insurance benefits, increasing cancer patient cure rates
As a part of the ‘Top 4 Severe Disease Coverage Extension Plan,’ the Ministry of Health and Welfare(Ministry Jin-yup Jung) is going to drastically extend application of the health insurance benefit from the 1st of Sep...
Super antibacterial ‘Tygacil’ continues to monopolization, succeeding in defending patent
The domestic exclusive license of a Pfizer’s super antibacterial drug ‘Tygacil(tigecycline)’ is expected to be extended.
The substance patent of Tygacil was expired this May, but the company has blocked other generic...
Bayer’s hemophilia therapy ‘Kogenate’ voluntarily returned in Korea
Bayer Korea will voluntarily collect back its hemophilia A therapy, Kogenate FS Inj.
It will be a follow-up action to prevent a quality issue since the company encountered disapproval of its products manufactured in ...
